Half of those who took part in the trial saw the length of their migraine reduce when they took the drug erenumab.
Powered by WPeMatico
Powered by WPeMatico
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.